Nikko Asset Management Exits CRISPR Therapeutics Stake

TL;DR

**Nikko Asset Management sold all its CRISPR Therapeutics shares.**

AI Summary

Nikko Asset Management Americas, Inc. filed an amended SC 13G/A on February 12, 2024, indicating a significant change in their beneficial ownership of CRISPR Therapeutics AG (CRSP) common shares as of December 31, 2023. The filing shows Nikko Asset Management Americas, Inc. now holds 0 shares with sole voting power, a decrease from their previous holdings. This matters to investors because it signals a complete divestment by a major institutional investor, which could be interpreted as a loss of confidence in CRISPR Therapeutics AG's future prospects.

Why It Matters

This filing reveals a major institutional investor, Nikko Asset Management Americas, Inc., has completely divested its stake in CRISPR Therapeutics AG, which could signal a lack of confidence in the company's future performance.

Risk Assessment

Risk Level: medium — The complete divestment by an institutional investor can sometimes precede negative news or indicate a perceived lack of future growth, posing a medium risk to current shareholders.

Analyst Insight

Investors should investigate the reasons behind Nikko Asset Management's complete divestment from CRISPR Therapeutics AG and consider if this signals a broader negative outlook for the company or the sector.

Key Numbers

• 0 — Sole Voting Power Shares (Nikko Asset Management Americas, Inc. now holds zero shares with sole voting power in CRISPR Therapeutics AG as of December 31, 2023.)

Key Players & Entities

• Nikko Asset Management Americas, Inc. (company) — the reporting person who filed the SC 13G/A
• CRISPR Therapeutics AG (company) — the issuer of the securities
• December 31, 2023 (date) — the date of the event requiring the filing
• February 12, 2024 (date) — the filing date of the SC 13G/A
• 0 (dollar_amount) — number of shares with sole voting power held by Nikko Asset Management Americas, Inc.

Forward-Looking Statements

• Other institutional investors may re-evaluate their positions in CRISPR Therapeutics AG following Nikko Asset Management's full divestment. (CRISPR Therapeutics AG) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• ef20021445_sc13ga.htm (SC 13G/A) — 69KB
• 0001140361-24-007107.txt ( ) — 71KB

From the Filing

SC 13G/A 1 ef20021445_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 1 NAMES OF REPORTING PERSONS Nikko Asset Management Americas, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,050,548 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,369,762 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,369,762 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.24% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Item 1. (a) Name of Issuer CRISPR Therapeutics AG (b) Address of Issuer's Principal Executive Offices Baarerstrasse 14 6300 Zug, Switzerland Item 2. (a) Name of Person Filing Nikko Asset Management Americas, Inc. (b) Address of Principal Business Office or, if none, Residence 605 Third Avenue, 38 th Floor, New York, NY 10158 (c) Citizenship USA (d) Title of Class of Securities Common Shares, nominal value CHF 0.03 (e) CUSIP Number H17182108 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J). (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,369,762 (b) Percent of class: 4.24% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 3,050,548 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 3,369,762 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . Item 6. See Exhibit A. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company See Exhibit A. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and ar

View Full Filing

View this SC 13G/A filing on SEC EDGAR